Aptuit names new executive chairman and interim CEO
Michael Griffith, the company’s founder and CEO since 2005, has resigned in order to pursue other opportunities. Mr Tyson is the former COO, president and CEO of Valeant
The US Food and Drug Administration (FDA) has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer.